Supplement Risk Limits Set “Substantially” Below Drugs By DSHEA, FDA Told
This article was originally published in The Tan Sheet
In the context of the Dietary Supplement Health & Education Act, the type of risk from dietary supplements that should be considered "significant or unreasonable" may be "substantially less serious than the types of risk that would be considered significant or unreasonable for drugs," according to April 4 congressional comments to FDA
You may also be interested in...
There is currently enough evidence of risk to remove ephedra from the market, Rep. Henry Waxman (D-Calif.) maintained at the Food & Drug Law Institute's Annual Educational Conference in Washington, D.C. April 1
Legislation to amend the Dietary Supplement Health & Education Act is a long-term goal of Sen. Richard Durbin (D-Ill.), according to his staff
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC